Zoetis price target raised to $260 from $250 at Barclays

Barclays analyst Balaji Prasad raised the firm’s price target on Zoetis to $260 from $250 and keeps an Overweight rating on the shares. With "significant unmet need" for osteoarthritis pain management, Librela and Solensia could add meaningful sales contribution to Zoetis over the next decade, the analyst tells investors in a research note. The firm believes both products combined have the potential to contribute $1.1B of revenues by 2030.